12 research outputs found
Recommended from our members
TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling
Thymic stromal lymphopoietin (TSLP) is a four-helix bundle cytokine that plays a critical role in the regulation of immune responses and in the differentiation of hematopoietic cells. TSLP signals through a heterodimeric receptor complex consisting of an interleukin-7 receptor α chain and a unique TSLP receptor (TSLPR) [also known as cytokine receptor-like factor 2 (CRLF2)]. Cellular targets of TSLP include dendritic cells, B cells, mast cells, regulatory T (Treg) cells and CD4+ and CD8+ T cells. The TSLP/TSLPR axis can activate multiple signaling transduction pathways including the JAK/STAT pathway and the PI-3 kinase pathway. Aberrant TSLP/TSLPR signaling has been associated with a variety of human diseases including asthma, atopic dermatitis, nasal polyposis, inflammatory bowel disease, eosinophilic eosophagitis and, most recently, acute lymphoblastic leukemia. A centralized resource of the TSLP signaling pathway cataloging signaling events is not yet available. In this study, we present a literature-annotated resource of reactions in the TSLP signaling pathway. This pathway map is publicly available through NetPath (http://www.netpath.org/), an open access signal transduction pathway resource developed previously by our group. This map includes 236 molecules and 252 reactions that are involved in TSLP/TSLPR signaling pathway. We expect that the TSLP signaling pathway map will provide a rich resource to study the biology of this important cytokine as well as to identify novel therapeutic targets for diseases associated with dysregulated TSLP/TSLPR signaling. Database URL: http://www.netpath.org/pathways?path_id=NetPath_2
Recommended from our members
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptorâlike factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling. In this study, we identify G935R, Y931C, and E864K mutations within the JAK2 kinase domain that confer resistance across a panel of JAK inhibitors, whether present in cis with JAK2 V617F (observed in MPNs) or JAK2 R683G (observed in B-ALL). G935R, Y931C, and E864K do not reduce the sensitivity of JAK2-dependent cells to inhibitors of heat shock protein 90 (HSP90), which promote the degradation of both wild-type and mutant JAK2. HSP90 inhibitors were 100â1,000-fold more potent against CRLF2-rearranged B-ALL cells, which correlated with JAK2 degradation and more extensive blockade of JAK2/STAT5, MAP kinase, and AKT signaling. In addition, the HSP90 inhibitor AUY922 prolonged survival of mice xenografted with primary human CRLF2-rearranged B-ALL further than an enzymatic JAK2 inhibitor. Thus, HSP90 is a promising therapeutic target in JAK2-driven cancers, including those with genetic resistance to JAK enzymatic inhibitors
Recommended from our members
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 lysine 27 trimethylation
Down syndrome confers a 20-fold increased risk of B cell acute lymphoblastic leukemia (B-ALL)1 and polysomy 21 is the most frequent somatic aneuploidy amongst all B-ALLs2. Yet, the mechanistic links between chr.21 triplication and B-ALL remain undefined. Here we show that germline triplication of only 31 genes orthologous to human chr.21q22 confers murine progenitor B cell self-renewal in vitro, maturation defects in vivo, and B-ALL with either BCR-ABL or CRLF2 with activated JAK2. Chr.21q22 triplication suppresses H3K27me3 in progenitor B cells and B-ALLs, and âbivalentâ genes with both H3K27me3 and H3K4me3 at their promoters in wild-type progenitor B cells are preferentially overexpressed in triplicated cells. Strikingly, human B-ALLs with polysomy 21 are distinguished by their overexpression of genes marked with H3K27me3 in multiple cell types. Finally, overexpression of HMGN1, a nucleosome remodeling protein encoded on chr.21q223â5, suppresses H3K27me3 and promotes both B cell proliferation in vitro and B-ALL in vivo
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
The genetics of angioimmunoblastic T-cell lymphoma (AITL) are very poorly understood. We defined the mutational landscape of AITL across 219 genes in 85 cases from the United States and Europe. We identified \ue2\u89\ua52 mutations in 34 genes, nearly all of which were not previously implicated in AITL. These included loss-of-function mutations in TP53 (n = 4), ETV6 (n = 3), CCND3 (n = 2), and EP300 (n = 5), as well as gain-of-function mutations in JAK2 (n = 2) and STAT3 (n = 4). TET2 was mutated in 65 (76%) AITLs, including 43 that harbored 2 or 3 TET2 mutations. DNMT3A mutations occurred in 28 (33%) AITLs; 100% of these also harbored TET2 mutations (P < .0001). Seventeen AITLs harbored IDH2 R172 substitutions, including 15 with TET2 mutations. In summary, AITL is characterized by high frequencies of overlapping mutations in epigenetic modifiers and targetable mutations in a subset of cases. \uc2\ua9 2014 by The American Society of Hematology
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myelproliferative neoplasms (MPNs) and other diseases with dependence on JAK2. We and others recently identified rearrangements of the CRLF2 cytokine receptor, which signals through JAK2, in a subset of B-cell acute lymphoblastic leukemias (B-ALL) 1-4. Here we show that B-ALL cells with CRLF2-rearrangements maintain JAK2 signaling in the presence of therapeutic concentrations of enzymatic JAK2 inhibitors. In contrast, destabilization and degradation of JAK2 through inhibition of heat shock protein 90 (HSP90) effectively blocks CRLF2 signaling and prolongs survival in mice xenografted with primary human B-ALL. We identify G935R, Y931C and E864K mutations within the JAK2 kinase domain that confer resistance to a panel of JAK2 inhibitors, whether involving JAK2 V617F (observed in MPNs) signaling through the erythropoietin receptor or JAK2 R683G (observed in B-ALL) signaling through CRLF2. None of the mutations affect sensitivity to HSP90 inhibitors. Thus, resistance to JAK2 enzymatic inhibitors can either result from persistent JAK2 signaling or kinase domain mutations and is overcome by inhibition of HSP90
Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2
Type II JAK2 inhibition in B-cell acute lymphoblastic leukemia
A variety of cancers depend on JAK2 signaling, including the high-risk subset of B-cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements. Type I JAK2 inhibitors induce JAK2 hyperphosphorylation in these leukemias and have limited activity. To overcome this, we developed the type II inhibitor NVP-CHZ868, which stabilizes JAK2 in an inactive conformation. CHZ868 potently suppressed the growth of CRLF2-rearranged human B-ALL cells, abrogated JAK2 signaling, and improved survival in mice with primary human or murine B-ALL. CHZ868 and dexamethasone synergistically induced apoptosis of CRLF2-rearranged human B-ALL cells and improved survival compared to CHZ868 alone. Together, these data provide the foundation for trials of type II JAK2 inhibition in patients with CRLF2-rearranged B-ALL and other JAK2-dependent disorders